论文部分内容阅读
作者分析了用Latamoxef(Lmox)治疗135例血液病并发重症感染的临床效果。男73、女62例。急性白血病67例(其中急性粒细胞性白血病30例),约占总数的一半,如加上成人T细胞白血病、慢性粒细胞白血病、慢性单核细胞性白血病、白血病前期、骨髓纤维化症等则达93例(70%),其它还有何杰金病及恶性淋巴瘤20例(14.8%),多发性骨髓瘤11例(8.1%)等。重症感染以败血症(11例)及疑似败血症(58例)最多,占51.1%,其次为肺炎39例(28.9%)。Lmox用量2～9g/d,多以2g
The authors analyzed the clinical efficacy of Latamoxef (Lmox) in the treatment of 135 blood diseases complicated by severe infections. Male 73, female 62 cases. 67 cases of acute leukemia (including 30 cases of acute myeloid leukemia), accounting for about half of the total, such as with adult T-cell leukemia, chronic myelogenous leukemia, chronic myelogenous leukemia, leukemia, myelofibrosis There were 93 cases (70%) with Hodgkin’s disease, 20 cases with malignant lymphoma (14.8%) and 11 cases with multiple myeloma (8.1%). Severe infection with sepsis (11 cases) and suspected sepsis (58 cases) the most, accounting for 51.1%, followed by 39 cases of pneumonia (28.9%). Lmox dosage 2 ~ 9g / d, mostly 2g